Brief Intervention for OCD Fears

Obsessive-compulsive Disorder Clinical Trial

Official title:

Brief Intervention for OCD Fears

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02790710
• Other study ID #: 7293 (OCD)
• Status: Withdrawn
• Phase: Phase 4
• Start date: June 2016
• Est. completion date: April 2023

Study information

• Verified date: April 2023
• Source: New York State Psychiatric Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.

Description:

Twenty subjects with OCD will be enrolled in the study. Participants will complete baseline assessments of fear and avoidance. Participants will be randomly assigned to a single dose of propranolol 40mg or placebo, administered immediately after a fear reactivation procedure. Primary outcome assessment will be OCD symptoms and avoidance behavior in a behavioral avoidance task 2 weeks after the intervention

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Principal Diagnosis of Obsessive-Compulsive Disorder

Exclusion Criteria:

• History of other serious psychiatric disorder

• Current Major Depressive Disorder

• Women who are pregnant or nursing

• Current use of psychiatric medication

• Persons planning to start another treatment during the study period

• Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder

Intervention

Drug:
• Propanolol
Active treatment
• Placebo

Locations

Country	Name	City	State
United States	New York State Psychiatric Institute	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
New York State Psychiatric Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Yale Brown Obsessive-Compulsive Scale	Total score on this Clinician-administered measure of OCD symptoms	2 weeks
Secondary	Behavioral Avoidance Task	Total number of steps completed (0-5) on this task assessing avoidance of OCD triggers	2 weeks